Clinical trial · Interventional
A Trial of ABI-007 in Patients With Advanced Non-Hematologic Malignancies
A Phase I Trial of ABI-007 Administered Weekly for Three Doses Every 4 Weeks in Patients With Advanced Non-hematologic Malignancies
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
This trial will treat patients with advanced (metastatic) cancer with a new chemotherapeutic agent that may be more readily tolerated than some standard therapies. Patients will be given the new chemotherapeutic medicine once a week, by intravenous route, for three weeks, followed by a rest week. Treatment will be repeated in four week cycles if the patient improves on the therapy, and if there are no adverse events that require withdrawal of medication.
Conditions
Conditions (2)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Metastases, Neoplasm | — | UNRESOLVED | — |
| Neoplasms | Neoplasm | ONTOLOGY_EXACT | 0.90 |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| ABI-007 | Drug | — | UNRESOLVED |
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
Show eligibility criteria text
* At least 18 years of age * Life expectancy of at least 2 months * Off all therapy for at least 3 weeks prior to study drug administration * Biopsy-proven diagnosis of advanced malignancy * Patients with solid tumors who have failed standard therapy * Karnofsky Performance Status of 70% or 0-2 SWOG Performance Status * Hemoglobin at least 9 * White Blood Cell count of at least 3000/mm3 with absolute neutrophil count of at least 1500/mm3 * Platelet count of at least 100,000/mm3 * Serum Creatinine less than 2 mg/dL * Transaminases less than 3X the upper limit of normal * Patient must provide informed consent * Serum Bilirubin less than 1.5 mg/dL
References
Publications (1)
- BACKGROUNDNyman DW, Campbell KJ, Hersh E, Long K, Richardson K, Trieu V, Desai N, Hawkins MJ, Von Hoff DD. Phase I and pharmacokinetics trial of ABI-007, a novel nanoparticle formulation of paclitaxel in patients with advanced nonhematologic malignancies. J Clin Oncol. 2005 Nov 1;23(31):7785-93. doi: 10.1200/JCO.2004.00.6148. PMID 16258082